Get started
Gilead Sciences, Inc. Shs Cert Deposito Arg Repr 1/4 ShGilead Sciences, Inc. Shs Cert Deposito Arg Repr 1/4 ShGilead Sciences, Inc. Shs Cert Deposito Arg Repr 1/4 Sh

Gilead Sciences, Inc. Shs Cert Deposito Arg Repr 1/4 Sh

No trades
See on Supercharts
OverviewFinancialsNewsIdeasMindsTechnicalsSeasonalsBonds

Chart


Full chart

Key facts today


Needham has raised the price target for Gilead Sciences to $140.00 per share, an increase from the previous target of $133.00.
Gilead Sciences has received a 'Sector Outperform' rating from Scotiabank, indicating a positive outlook for the company's performance in the sector.
Analyze the impactAnalyze the impact

Key stats


Market capitalization
‪153.10 B‬ USD
Dividend yield (indicated)
2.43%
Price to earnings Ratio (TTM)
21.65
Basic EPS (TTM)
1.40 USD
Net income (FY)
‪426.34 M‬ USD
Revenue (FY)
‪25.52 B‬ USD
Shares float
—
Beta (1Y)
−0.10

About Gilead Sciences, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Daniel P. O'Day
Website
gilead.com
Headquarters
Foster City
Founded
1987
ISIN
ARBCOM4601C4
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Check out other big names from the same industry as GILDD.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Highest yielding bonds


GILD5939386
Gilead Sciences, Inc. 5.6% 15-NOV-2064
Yield to maturity
5.59%
Maturity date
Nov 15, 2064
GILD5939385
Gilead Sciences, Inc. 5.5% 15-NOV-2054
Yield to maturity
5.50%
Maturity date
Nov 15, 2054
GILD5648609
Gilead Sciences, Inc. 5.55% 15-OCT-2053
Yield to maturity
5.49%
Maturity date
Oct 15, 2053
US375558BK8
Gilead Sciences, Inc. 4.15% 01-MAR-2047
Yield to maturity
5.47%
Maturity date
Mar 1, 2047
GISE
Gilead Sciences, Inc. 4.75% 01-MAR-2046
Yield to maturity
5.47%
Maturity date
Mar 1, 2046
GILD4184058
Gilead Sciences, Inc. 4.5% 01-FEB-2045
Yield to maturity
5.40%
Maturity date
Feb 1, 2045
GILD5050849
Gilead Sciences, Inc. 2.8% 01-OCT-2050
Yield to maturity
5.39%
Maturity date
Oct 1, 2050
GILD.GO
Gilead Sciences, Inc. 5.65% 01-DEC-2041
Yield to maturity
5.29%
Maturity date
Dec 1, 2041
GILD4104362
Gilead Sciences, Inc. 4.8% 01-APR-2044
Yield to maturity
5.26%
Maturity date
Apr 1, 2044
US375558BS1
Gilead Sciences, Inc. 2.6% 01-OCT-2040
Yield to maturity
5.19%
Maturity date
Oct 1, 2040
GISG
Gilead Sciences, Inc. 4.0% 01-SEP-2036
Yield to maturity
4.85%
Maturity date
Sep 1, 2036

See all GILDD bonds 

Sparks


Curated watchlists where GILDD is featured.

See all sparks